DeepMed Research

Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2016-11-21

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 47

Registration Number: NCT02969837

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
NorthShore University Health System, Evanston, Illinois, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

In-School Evaluation of Bystander: A Game-Based Intervention for Sexual Violence Prevention

Not Applicable

Completed

Conditions: Bystander Behavioral Intentions

Interventions: Behavioral: Bystander, a game-based bystander intervention program
Behavioral: Infection City, a game-based program about meningitis

First Posted Date: 2016-09-29

Last Posted Date: 2023-02-23

Lead Sponsor: University of Chicago

Target Recruit Count: 601

Registration Number: NCT02919098

Locations: 🇺🇸
University of Chicao, Chicago, Illinois, United States

Cannabidiol and Emotional Stimuli

Not Applicable

Completed

Conditions: Drug Addiction

Interventions: Drug: Placebo
Drug: Cannabidiol

First Posted Date: 2016-09-15

Last Posted Date: 2019-08-28

Lead Sponsor: University of Chicago

Target Recruit Count: 38

Registration Number: NCT02902081

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Shift Work and Risk of Cardio-vascular Disease

Completed

Conditions: Shift-Work Sleep Disorder

Interventions: Other: Sleep, Dietary and Cardio-metabolic Measurements

First Posted Date: 2016-09-15

Last Posted Date: 2023-06-02

Lead Sponsor: University of Chicago

Target Recruit Count: 86

Registration Number: NCT02901860

Advanced HIV Prevention (PrEP Chicago)

Not Applicable

Completed

Conditions: HIV

Interventions: Other: Control Group
Behavioral: PrEP Intervention Group

First Posted Date: 2016-09-12

Last Posted Date: 2024-01-18

Lead Sponsor: University of Chicago

Target Recruit Count: 424

Registration Number: NCT02896699

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Increasing the Reach of Promising Dropout Prevention Programs: Examining the Trade-offs Between Scale and Effectiveness

Not Applicable

Conditions: Educational Achievement

Interventions: Other: SAGA Innovations
Other: Scale-up tutors
Other: Standard Tutors

First Posted Date: 2016-09-05

Last Posted Date: 2020-04-24

Lead Sponsor: University of Chicago

Target Recruit Count: 6600

Registration Number: NCT02889640

Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation

Phase 4

Completed

Conditions: Smoking Cessation
Alcohol Drinking

Interventions: Drug: Chantix
Behavioral: Behavioral Counseling Sessions
Drug: NicodermCQ
Drug: Placebo

First Posted Date: 2016-08-08

Last Posted Date: 2021-09-27

Lead Sponsor: University of Chicago

Target Recruit Count: 122

Registration Number: NCT02859142

Locations: 🇺🇸
Clinical Addictions Research Laboratory, Chicago, Illinois, United States

A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients

Phase 2

Withdrawn

Conditions: Parkinson's Disease

Interventions: Drug: Duloxetine
Drug: Donepezil
Drug: Modafinil

First Posted Date: 2016-08-05

Last Posted Date: 2017-12-12

Lead Sponsor: University of Chicago

Registration Number: NCT02857244

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

Milk Thistle in Body Dysmorphic Disorder

Phase 2

Withdrawn

Conditions: Body Dysmorphic Disorder

Interventions: Drug: Placebo
Drug: Milk Thistle

First Posted Date: 2016-07-25

Last Posted Date: 2022-12-28

Lead Sponsor: University of Chicago

Registration Number: NCT02843451

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Phase 2

Active, not recruiting

Conditions: Head and Neck Cancer
Squamous Cell Carcinoma of the Head and Neck

Interventions: Drug: Placebo
Drug: Pembrolizumab

First Posted Date: 2016-07-22

Last Posted Date: 2024-05-13

Lead Sponsor: University of Chicago

Target Recruit Count: 100

Registration Number: NCT02841748

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Emory University Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 1 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy